Talazoparib (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Talazoparib" in English language version.

refsWebsite

Global rank English rank

12web.archive.org

1^st place

5fda.gov

447^th place

338^th place

5nih.gov

4^th place

2tga.gov.au

3,984^th place

2,622^nd place

2doi.org

2^nd place

1canada.ca

1,712^th place

1,063^rd place

1hres.ca

low place

1medicines.org.uk

3,823^rd place

2,387^th place

1europa.eu

68^th place

117^th place

1medivation.com

low place

1businesswire.com

615^th place

407^th place

1pmlive.com

low place

1semanticscholar.org

11^th place

8^th place

1bmrn.com

low place

1onclive.com

low place

bmrn.com

investors.bmrn.com

Biomarin (24 August 2015). "Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a Potent PARP Inhibitor, From BioMarin" (Press release). Archived from the original on 5 February 2017. Retrieved 21 November 2016.

businesswire.com

"European Commission Approves Talzenna (talazoparib) for Patients with Inherited (Germline) BRCA-Mutated Locally Advanced or Metastatic Breast Cancer" (Press release). Pfizer Inc. Archived from the original on 22 September 2020. Retrieved 23 June 2019.

canada.ca

health-products.canada.ca

"Talzenna Product information". Health Canada. 25 April 2012. Archived from the original on 30 May 2022. Retrieved 29 May 2022.

doi.org

Brown JS, Kaye SB, Yap TA (March 2016). "PARP inhibitors: the race is on". British Journal of Cancer. 114 (7): 713–5. doi:10.1038/bjc.2016.67. PMC 4984871. PMID 27022824.
Shen Y, Aoyagi-Scharber M, Wang B (June 2015). "Trapping Poly(ADP-Ribose) Polymerase". The Journal of Pharmacology and Experimental Therapeutics. 353 (3): 446–57. doi:10.1124/jpet.114.222448. PMID 25758918. S2CID 9810541.

europa.eu

ema.europa.eu

"Talzenna EPAR". European Medicines Agency (EMA). 8 July 2019. Archived from the original on 19 May 2020. Retrieved 10 March 2020.

fda.gov

"FDA approves Lynparza to treat advanced ovarian cancer". U.S. Food and Drug Administration (FDA) (Press release). 19 December 2014. Archived from the original on 19 December 2014. Retrieved 16 December 2019.
"FDA approves talazoparib for gBRCAm HER2-negative locally advanced or". U.S. Food and Drug Administration. 16 October 2018. Retrieved 8 March 2024. This article incorporates text from this source, which is in the public domain.
"FDA approves talazoparib with enzalutamide for HRR gene-mutated metast". U.S. Food and Drug Administration. 20 June 2023. Retrieved 8 March 2024. This article incorporates text from this source, which is in the public domain.
"Drug Trial Snapshot: Talzenna". U.S. Food and Drug Administration (FDA). 16 October 2018. Retrieved 9 March 2024. This article incorporates text from this source, which is in the public domain.

accessdata.fda.gov

"Drug Approval Package: Talzenna (talazoparib)". U.S. Food and Drug Administration (FDA). 29 October 2018. Archived from the original on 30 October 2020. Retrieved 10 March 2020.

hres.ca

hpr-rps.hres.ca

"Summary Basis of Decision (SBD) for Talzenna". Health Canada. 23 October 2014. Archived from the original on 31 May 2022. Retrieved 29 May 2022.

medicines.org.uk

"Talzenna 0.25 mg hard capsules - Summary of Product Characteristics (SmPC)". (emc). 1 June 2021. Archived from the original on 9 July 2021. Retrieved 9 July 2021.

medivation.com

Medivation Inc. "Talazoparib". Archived from the original on 8 June 2017. Retrieved 21 November 2016.

nih.gov

dailymed.nlm.nih.gov

"Talzenna- talazoparib capsule". DailyMed. 4 September 2023. Archived from the original on 30 July 2023. Retrieved 13 November 2023.
"Talzenna- talazoparib capsule". DailyMed. 4 September 2023. Archived from the original on 29 May 2023. Retrieved 13 November 2023.

pubmed.ncbi.nlm.nih.gov

Brown JS, Kaye SB, Yap TA (March 2016). "PARP inhibitors: the race is on". British Journal of Cancer. 114 (7): 713–5. doi:10.1038/bjc.2016.67. PMC 4984871. PMID 27022824.
Shen Y, Aoyagi-Scharber M, Wang B (June 2015). "Trapping Poly(ADP-Ribose) Polymerase". The Journal of Pharmacology and Experimental Therapeutics. 353 (3): 446–57. doi:10.1124/jpet.114.222448. PMID 25758918. S2CID 9810541.

ncbi.nlm.nih.gov

Brown JS, Kaye SB, Yap TA (March 2016). "PARP inhibitors: the race is on". British Journal of Cancer. 114 (7): 713–5. doi:10.1038/bjc.2016.67. PMC 4984871. PMID 27022824.

onclive.com

Inman S (25 August 2015). "Medivation Acquires BioMarin's PARP Inhibitor Talazoparib". Archived from the original on 21 November 2016. Retrieved 21 November 2016.

pmlive.com

"Pfizer's Talzenna combination receives EC approval for metastatic prostate cancer". PMLive. 10 January 2024. Retrieved 11 January 2024.

semanticscholar.org

api.semanticscholar.org

Shen Y, Aoyagi-Scharber M, Wang B (June 2015). "Trapping Poly(ADP-Ribose) Polymerase". The Journal of Pharmacology and Experimental Therapeutics. 353 (3): 446–57. doi:10.1124/jpet.114.222448. PMID 25758918. S2CID 9810541.

tga.gov.au

"Talzenna APMDS". Therapeutic Goods Administration (TGA). 26 May 2022. Retrieved 10 March 2024.
"Talzenna (Pfizer Australia Pty Ltd)". Therapeutic Goods Administration (TGA). 13 September 2024. Retrieved 15 September 2024.

web.archive.org

"Talzenna Product information". Health Canada. 25 April 2012. Archived from the original on 30 May 2022. Retrieved 29 May 2022.
"Summary Basis of Decision (SBD) for Talzenna". Health Canada. 23 October 2014. Archived from the original on 31 May 2022. Retrieved 29 May 2022.
"Talzenna 0.25 mg hard capsules - Summary of Product Characteristics (SmPC)". (emc). 1 June 2021. Archived from the original on 9 July 2021. Retrieved 9 July 2021.
"Talzenna- talazoparib capsule". DailyMed. 4 September 2023. Archived from the original on 30 July 2023. Retrieved 13 November 2023.
"Talzenna- talazoparib capsule". DailyMed. 4 September 2023. Archived from the original on 29 May 2023. Retrieved 13 November 2023.
"Talzenna EPAR". European Medicines Agency (EMA). 8 July 2019. Archived from the original on 19 May 2020. Retrieved 10 March 2020.
Medivation Inc. "Talazoparib". Archived from the original on 8 June 2017. Retrieved 21 November 2016.
"FDA approves Lynparza to treat advanced ovarian cancer". U.S. Food and Drug Administration (FDA) (Press release). 19 December 2014. Archived from the original on 19 December 2014. Retrieved 16 December 2019.
"European Commission Approves Talzenna (talazoparib) for Patients with Inherited (Germline) BRCA-Mutated Locally Advanced or Metastatic Breast Cancer" (Press release). Pfizer Inc. Archived from the original on 22 September 2020. Retrieved 23 June 2019.
"Drug Approval Package: Talzenna (talazoparib)". U.S. Food and Drug Administration (FDA). 29 October 2018. Archived from the original on 30 October 2020. Retrieved 10 March 2020.
Biomarin (24 August 2015). "Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a Potent PARP Inhibitor, From BioMarin" (Press release). Archived from the original on 5 February 2017. Retrieved 21 November 2016.
Inman S (25 August 2015). "Medivation Acquires BioMarin's PARP Inhibitor Talazoparib". Archived from the original on 21 November 2016. Retrieved 21 November 2016.